Catalent Acquires Relthy in Brazil

Catalent Pharma Solutions has acquired Relthy Laboratórios in Brazil, expanding its softgel business and operations in South America. Relthy produces softgel encapsulated Vitamin, Mineral and Supplement (VMS) products, as well as prescription and OTC products for the Brazilian market. Relthy has 350 employees and a production capacity of two billion capsules per year. Relthy’s management team will join Catalent. Financial terms were not disclosed.
 
The acquisition provides Catalent entry into the VMS nutritional market and expands its primary and secondary packaging capabilities in Brazil. Relthy is Catalent’s 11th softgel facility in its global network and will complement its existing pharmaceutical and OTC focused South American facilities in Sorocaba, Brazil and Buenos Aires, Argentina.
 
“This investment will benefit our domestic and international customers as it draws on both parties’ complementary capabilities to holistically address market needs,” said Dr. Aris Gennadios, president of Softgel Technologies, Catalent Pharma Solutions. “Brazil represents a key strategic location for Catalent and its customers, and this acquisition will create significant growth opportunities.”
 
Paulo Vianna, chairman and chief executive officer of Relthy Laboratórios, said, “The deal brings together Catalent’s expertise in OTC and Rx manufacturing, deep regulatory compliance knowledge, its global R&D resources and advanced capabilities and combines these with our existing domestic customer base and proven ability to respond to local customer needs and market requirements.”